TY - JOUR
T1 - Reward and Punishment Sensitivity are Associated with Cross-disorder Traits
AU - Portengen, Christel M.
AU - Sprooten, Emma
AU - Zwiers, Marcel P.
AU - Hoekstra, Pieter J.
AU - Dietrich, Andrea
AU - Holz, Nathalie E.
AU - Aggensteiner, Pascal M.
AU - Banaschewski, Tobias
AU - Schulze, Ulrike M.E.
AU - Saam, Melanie C.
AU - Craig, Michael C.
AU - Sethi, Arjun
AU - Santosh, Paramala
AU - Ouriaghli, Ilyas Sagar
AU - Castro-Fornieles, Josefina
AU - Rosa, Mireia
AU - Arango, Celso
AU - Penzol, María José
AU - Werhahn, Julia E.
AU - Brandeis, Daniel
AU - Walitza, Susanne
AU - Oldehinkel, Marianne
AU - Franke, Barbara
AU - Buitelaar, Jan K.
AU - Naaijen, Jilly
N1 - Funding Information:
This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602805 (Aggressotype), 603016 (MATRICS), 728018 (Eat2beNICE) and 667302 (CoCA). This work reflects only the authors? views, and the European Union is not liable for any use that may be made of the information contained herein. E.S. is supported by a Hypatia Fellowship (Radboudumc) and a NARSAD Young Investigator Grant (ID:25034). B.F. is supported by the Dutch National Science Agenda through the NWA-NeurolabNL project (grant 400 17 602). J.N. is supported by a VENI grant of the Netherlands Organisation for Scientific Research (NWO) (V1.Veni.194.032). We gratefully thank Hanneke den Ouden for the task code and basic analysis code. We gratefully acknowledge and thank all the participants and their families for their enthusiastic participation in the study. The authors would also like to thank all other PhD students, post-docs, and research assistants for their involvement in data-collection.
Funding Information:
T Banaschewski served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Medice, Novartis, Oxford outcomes, PCM scientific, Shire and Viforpharma. He received conference support or speaker's fee by Medice, Novartis and Shire. He is/has been involved in clinical trials conducted by Shire & Viforpharma. The present work is unrelated to the grants and relationships noted earlier. C Arango has been a consultant to or has received honoraria or grants from Acadia, Ambrosseti, Caja Navarra, CIBERSAM, Fundación Alicia Koplowitz, Forum, Instituto de Salud Carlos III, Gedeon Richter, Janssen Cilag, Lundbeck, Merck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Roche, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovio and Takeda. S. Walitza has received in the last 5 years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz. S. Walitza has received lecture honoraria from Opopharma in the last 5 years. Her work was supported in the last 5 years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Müller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds. D Brandeis serves as an unpaid scientific advisor for an EU-funded Neurofeedback trial unrelated to the present work. JC Glennon has acted as a consultant for Boehringer Ingelheim GmbH. B Franke received an educational speaking fee from Medice. JK Buitelaar has been consultant to/member of advisory board of and/or speaker for Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Shering Plough, UCB, Shire, Novartis, and Servier. He is not an employee of any of these companies, nor a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties. The other authors do not report any biomedical financial interests or potential conflicts of interest.
Funding Information:
This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602805 (Aggressotype), 603016 (MATRICS), 728018 (Eat2beNICE) and 667302 (CoCA). This work reflects only the authors’ views, and the European Union is not liable for any use that may be made of the information contained herein. E.S. is supported by a Hypatia Fellowship (Radboudumc) and a NARSAD Young Investigator Grant (ID:25034). B.F. is supported by the Dutch National Science Agenda through the NWA-NeurolabNL project (grant 400 17 602). J.N. is supported by a VENI grant of the Netherlands Organisation for Scientific Research (NWO) (V1.Veni.194.032). We gratefully thank Hanneke den Ouden for the task code and basic analysis code. We gratefully acknowledge and thank all the participants and their families for their enthusiastic participation in the study. The authors would also like to thank all other PhD students, post-docs, and research assistants for their involvement in data-collection.
Publisher Copyright:
© 2021
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Reversal learning deficits following reward and punishment processing are observed across disruptive behaviors (DB) and attention-deficit/hyperactivity disorder (ADHD), and have been associated with callous-unemotional (CU) traits. However, it remains unknown to what extent these altered reinforcement sensitivities are linked to the co-occurrence of oppositional traits, ADHD symptoms, and CU traits. Reward and punishment sensitivity and perseverative behavior were therefore derived from a probabilistic reversal learning task to investigate reinforcement sensitivity in participants with DB (n=183, ODD=62, CD=10, combined=57, age-range 8-18), ADHD (n=144, age-range 11-28), and controls (n=191, age-range 8-26). The SNAP-IV and Conners rating scales were used to assess oppositional and ADHD traits. The Inventory of CU traits was used to assess CU traits. Decreased reward sensitivity was associated with ADHD symptom severity (p=0.018) if corrected for oppositional symptoms. ADHD symptomatology interacted with oppositional behavior on perseveration (p=0.019), with the former aggravating the effect of oppositional behavior on perseveration and vice versa. Within a pooled sample, reversal learning alterations were associated with the severity of ADHD symptoms, underpinned by hyposensitivity to reward and increased perseveration. These results show ADHD traits, as opposed to oppositional behavior and CU traits, is associated with decreased reward-based learning in adolescents and adults.
AB - Reversal learning deficits following reward and punishment processing are observed across disruptive behaviors (DB) and attention-deficit/hyperactivity disorder (ADHD), and have been associated with callous-unemotional (CU) traits. However, it remains unknown to what extent these altered reinforcement sensitivities are linked to the co-occurrence of oppositional traits, ADHD symptoms, and CU traits. Reward and punishment sensitivity and perseverative behavior were therefore derived from a probabilistic reversal learning task to investigate reinforcement sensitivity in participants with DB (n=183, ODD=62, CD=10, combined=57, age-range 8-18), ADHD (n=144, age-range 11-28), and controls (n=191, age-range 8-26). The SNAP-IV and Conners rating scales were used to assess oppositional and ADHD traits. The Inventory of CU traits was used to assess CU traits. Decreased reward sensitivity was associated with ADHD symptom severity (p=0.018) if corrected for oppositional symptoms. ADHD symptomatology interacted with oppositional behavior on perseveration (p=0.019), with the former aggravating the effect of oppositional behavior on perseveration and vice versa. Within a pooled sample, reversal learning alterations were associated with the severity of ADHD symptoms, underpinned by hyposensitivity to reward and increased perseveration. These results show ADHD traits, as opposed to oppositional behavior and CU traits, is associated with decreased reward-based learning in adolescents and adults.
KW - attention deficit/hyperactivity disorder
KW - Callous-unemotional traits
KW - oppositional defiant disorder
KW - reversal learning
KW - reward and punishment sensitivity
UR - http://www.scopus.com/inward/record.url?scp=85100699392&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2021.113795
DO - 10.1016/j.psychres.2021.113795
M3 - Article
AN - SCOPUS:85100699392
SN - 0165-1781
VL - 298
JO - Psychiatry Research
JF - Psychiatry Research
M1 - 113795
ER -